Insights - Bluebird’s new manufacturing process confirmed the improvement in clinical benefits and their partnered CAR-T candidate with Celgene reported “unheard of” responses in myeloma. BLUE soared … Continue Reading
Read NowInsights - With ASH approaching this weekend, Bluebird investors are focused on upcoming datasets in β- thalassemia (TDT) and sickle cell disease (SCD) at ASH. A big … Continue Reading
Read NowInsights - Add to SELB position under $11/share after decline from November data was overdone With upcoming catalysts in Q1 2018, we think SELB will have a … Continue Reading
Premium: Read NowInsights - GW Pharma (GWPH) announced the submission of its rolling NDA for their cannabidiol candidate Epidiolex, treating rare epilepsy conditions Lennox-Gastaut Syndrome and Dravet Syndrome. At … Continue Reading
Premium: Read NowInsights - Trillium (TRIL) has been a legacy name for PropThink as we’ve been covering it since 2014. With data being presented at ASH conference on December … Continue Reading
Read NowInsights - Join us for this exciting webinar with Prothink’s Analysts Monday, November 29, 2017 from 2:00-3:00 (EST) Successfully trading and investing in development-stage healthcare companies is … Continue Reading
Read NowInsights - Selecta (SELB) announced that it would report updated patient data from the ongoing Phase 2 trial of its lead product candidate, SEL-212, at the American College … Continue Reading
Read Now
